Shanghai Bio-heart Biological Technology Co Ltd Sustainability Reports
The company is a medical device company primarily engaged in the research, development, and commercialization of interventional cardiovascular devices. Its core product candidates include bioresorbable scaffolds for percutaneous coronary intervention procedures and renal denervation systems for treating hypertension.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
FIGI: BBG013JZV054
5 reports from 2021 to 2025
- Shanghai Bio-heart Biological Technology Co Ltd 2025 Annual Report
- Shanghai Bio-heart Biological Technology Co Ltd 2024 Annual Report
- Shanghai Bio-heart Biological Technology Co Ltd 2023 Annual Report
- Shanghai Bio-heart Biological Technology Co Ltd 2022 Annual Report
- Shanghai Bio-heart Biological Technology Co Ltd 2021 Annual Report